J&J
J&J seeks end to Doxil shortage as Ben Venue signs consent decree
January 28, 2013Manufacturing and Production Ben Venue, Boehringer, Caelyx, Doxil, J&J, JJ, Janssen
Johnson & Johnson says it has taken steps to establish new supplies of its cancer drug Doxil/Caelyx, which remains in …
Zytiga extended in EU
January 15, 2013Sales and Marketing EU, J&J, JJ, Janssen, Zytiga
Janssen is celebrating the European Commission’s decision to extend the licence for its prostate cancer treatment Zytiga. The once-daily pill …
FDA vote on J&J diabetes drug
January 10, 2013Sales and Marketing EU, FDA, J&J, JJ, Janssen, canagliflozin
Key advisers to the FDA are meeting today to decide whether Janssen Pharmaceuticals’ type II diabetes drug canagliflozin is safe …
Eugene Washington appointed to J&J Board of directors
November 13, 2012Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eugene Washington, J&J, JJ
Dr Eugene Washington has been appointed to the Board of directors at Johnson & Johnson. Washington serves as vice chancellor …
J&J profits down in Q3
October 17, 2012Sales and Marketing J&J, JJ, Johnson & Johnson, Q3, Risperdal
Johnson & Johnson has reported a 6.5% year-on-year sales increase to $17.1 billion in the third quarter of 2012, a …
Johnson & Johnson revamps manufacturing once again
October 15, 2012Manufacturing and Production Gurabo, J&J, JJ, Puerto Rico
Johnson & Johnson continues to restructure its manufacturing network, expanding production at plants in Puerto Rico whilst setting up a …
J&J cancer drugs get EU approval
October 2, 2012Sales and Marketing Cancer, Dacogen, EU, J&J, JJ, Velcade
Two of Johnson & Johnson’s key cancer drugs have been shown the green light from the European Commission. Janssen-Cilag International’s …
Amgen names Ray Jordan senior VP Corporate Affairs
September 24, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, J&J, JJ, Ray Jordan
Amgen has announced the appointment of ex-J&J comms leader Ray Jordan to the new position of senior vice president, Corporate …
Sandra Peterson joins J&J’s executive committee
September 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Sandra Peterson
Sandra Peterson will join Johnson & Johnson on 1 December as Group Worldwide chairman and member of the company’s executive …
J&J sets up life science centres
September 19, 2012Business Services, Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, R&D, innovation
Johnson & Johnson is to set up what it calls regional innovation centres in a bid to speed up the …
Smoke and fire in J&J Code breach
August 15, 2012Sales and Marketing Champix, J&J, JJ, Johnson and Johnson, PMCPA, Pfizer
Johnson & Johnson has been censured for breaking the ABPI Code of Practice in printed information about its smoking cessation …
J&J expects consent decree to extend through ‘most of 2013’
July 30, 2012Manufacturing and Production FDA, J&J, JJ, McNeil, OTC, recall
Johnson & Johnson has said it expects the production capacity issues affecting two plants covered by a consent decree with …
New J&J chief still struggling with scandals
July 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Risperdal, Weldon, Xarelto, Zytiga
Johnson & Johnson has just released its Q2 figures showing sales fell back in the second quarter, a 3.5% growth …
Janssen submits tuberculosis pill to FDA
July 4, 2012Research and Development, Sales and Marketing Bedaquiline, FDA, J&J, JJ, Janssen, tuberculosis
Janssen has submitted its investigational tuberculosis pill bedaquiline for review by the FDA. The firm is seeking a licence for …
FDA rejects licence extension for Xarelto
June 26, 2012Sales and Marketing ACS, Bayer, FDA, J&J, JJ, Pradaxa, Xarelto
The FDA has set a Complete Response Letter to Bayer and J&J over its blood thinner Xarelto. The firms, which …
